A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
A Phase Ib Study With a Safety lead-in Cohort and Expansion Phase, of the Safety, Tolerability, Biological Effect, and Efficacy of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer
Sponsor: Banc de Sang i Teixits
Terminated
Slow recruitment rate
Other terminated trials from Banc de Sang i Teixits
This PHASE1 trial investigates Breast Neoplasms and is currently terminated or withdrawn. Banc de Sang i Teixits leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jul 2022 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Banc de Sang i Teixits
- Clinica Universidad de Navarra, Universidad de Navarra
- Hospital del Mar
- Puerta de Hierro University Hospital
- Vall d'Hebron Institute of Oncology
For direct contact, visit the study record on ClinicalTrials.gov .